** Shares of Delaware-based drug developer Palatin Technologies PTN.A down 11% to 89 cents
** Co, which develops treatments of diseases such as autoimmune and dry eye diseases, launches stock offering
** PTNA to sell up to $6 million common shares through Alliance Global Partners acting as its sales agent
** Co has ~26.01 mln shares outstanding for a roughly $26 mln market value and ~18.9 mln shares of public float - LSEG
** Avg rating among 2 analysts is "buy" with $17 median PT - LSEG
** In the last 12 months, stock has fallen 50.7%
(Reporting by Siddhi Mahatole)
((siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。